Sanjivani Paranteral Ltd (SANJIVIN) — shareholding pattern, promoter holding, financials and share price
About Sanjivani Paranteral Ltd (SANJIVIN)
Sanjivani Paranteral Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SANJIVIN and on the BSE under scrip code 531569. Its ISIN is INE860D01013.
Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company [1]
Sanjivani Paranteral Limited is a WHO‑GMP certified Indian pharmaceutical manufacturer focused on sterile injectables and oral solid dosage forms, exporting to over 25 countries and operating manufacturing facilities in Navi Mumbai, Dehradun, Pune (SPL Infusion) and Prague (Alevia JV) while serving hospital and distributor channels in emerging markets.
Q3 FY26 performance was robust: standalone revenue of INR208.6 million (up 20.3% YoY), EBITDA of INR38.8 million (up 35.7% YoY) and PAT of INR26.2 million (up 37.8% YoY), with exports contributing roughly 77% of revenue and consolidated numbers showing slightly stronger YoY growth driven by new subsidiaries.
Listed peers in Pharmaceuticals: Achyut Healthcare Ltd, Accretion Nutraveda Ltd, Oxygenta Pharmaceutical Ltd, Accretion Pharmaceuticals Ltd, Parnax Lab Ltd, Bio Medica Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹144 a share on 10 Jul 2026, Sanjivani Paranteral Ltd (SANJIVIN) was valued at a price-to-earnings ratio of 26.4x against an industry P/E of 36.41x and a price-to-book of 4.66x on a book value of ₹30.93 per share as of Mar 2025. Solomo computes return on equity of 17.63% and return on capital employed of 22.06% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 26.4x
- Industry P/E
- 36.41x
- P/B
- 4.66x
- EPS (TTM)
- ₹5.45
- Book value / share
- ₹30.93
- ROE
- 17.63%
- ROCE
- 22.06%
- ROA
- 8.57%
- Debt / equity
- 0.21x
- Dividend yield
- 0.35%
- EBITDA margin
- 16.59%
- 52-week range
- ₹126 – ₹268.8
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sanjivani Paranteral Ltd (SANJIVIN) reported revenue of ₹68.67 crore, net profit of ₹6.69 crore and earnings per share of ₹5.45. That compares with revenue of ₹70.1 crore and net profit of ₹8.09 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹13.21 crore and net profit ₹0.55 crore (consolidated).
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue (₹ cr) | 54.41 | 70.1 | 68.67 |
| Net profit (₹ cr) | 6.17 | 8.09 | 6.69 |
| EPS (₹) | 5.28 | 6.81 | 5.45 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -5.40% | 33.78% | 31.81% | 28.84% |
| Profit growth | - | - | 18.68% | 31.12% |
| Stock price CAGR | 19% | 43% | 29% | -37% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 31.56% of Sanjivani Paranteral Ltd (SANJIVIN) (up 0.3 pp QoQ) and domestic institutional investors (DII) hold 5.45%. Market capitalisation was ₹177 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Suresh Pukhraj Jain . 7.05%, Kanta Suresh Jain . 6.01%, India Equity Fund 1 4.97%, Sun Capital Advisory Services Private Limited 4.24%, Ashish Kacholia 3.01%, Usha Ravindra Bhat 2.66%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 31.56% | - | - | 5.45% | 68.44% |
| Mar 2026 | 31.26% | - | - | 6.04% | 68.74% |
| Dec 2025 | 31.2% | - | - | 6.04% | 68.8% |
| Sep 2025 | 31.2% | - | - | 6.03% | 68.8% |
| Jun 2025 | 28.87% | - | - | 6.15% | 71.13% |
| Mar 2025 | 28.87% | - | - | 6.15% | 71.13% |
| Dec 2024 | 27.67% | - | - | 6.25% | 72.33% |
| Sep 2024 | 27.67% | - | - | 6.25% | 72.33% |